Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
-
BT7480 to be presented in a "New Drugs on the Horizon" session; on-track to enter the clinic in 2H'21
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a "New Drugs on the Horizon" session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and